AMRX — Amneal Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $6.70bn
- $9.39bn
- $3.02bn
Brief: Amneal Announces New Data From Phase 3 Study
Brief: Amneal Announces Expanded Coverage For Crexont® To Enhance Access For Parkinson’S Disease Patients In The U.S.
Brief: Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
U.S. STOCKS ON THE MOVE-BridgeBio Pharma, NetApp, Talen Energy
U.S. STOCKS ON THE MOVE-Recursion Pharmaceuticals, DoubleVerify Holdings, Praxis Precision Medicines
Amneal Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
U.S. STOCKS ON THE MOVE-SoundHound AI, Duolingo, Owens & Minor
Amneal Pharma rises on strong 2025 revenue forecast, Q4 revenue beat
U.S. STOCKS ON THE MOVE-Starbucks, Bristol Myers Squibb, Home Depot
U.S. STOCKS ON THE MOVE-BioMarin, Azul, Sun Communities
U.S. STOCKS ON THE MOVE- Twilio, Bath & Body Works, Wingstop
U.S. STOCKS ON THE MOVE-Nike, Domino's Pizza, Apple
Amneal Pharma rises; J.P.Morgan upgrades stock, raises PT
U.S. RESEARCH ROUNDUP-Amneal pharma, Aramark, Bluebird Bio
Brief: Amneal Launches Mesalamine And Receives U.S. FDA Approval For Lenalidomide
Teva loses US appeal to keep inhaler patents on FDA protected drug list (updated)
Teva loses US appeal to keep inhaler patents on FDA protected drug list
Brief: Amneal Resubmits DHE Autoinjector New Drug Application And Receives U.S. FDA Approval Of Exenatide
Amneal Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary